Up a level |
Journal Article
Borchmann, P., Viardot, A., Wermke, M., Subklewe, M., Siddiqi, T., Jaeger, U., Hasskarl, J. and Abramson, J. S. (2018). Results of the phase I transcend NHL 001 trial of JCAR017 support the phase II transcend world study of this Chimeric Antigen Receptor (CAR) T-Cell therapy in patients (Pts) with aggressive B-Cell Non-Hodgkin Lymphoma (B-NHL). Oncol. Res. Treat., 41. S. 37 - 38. BASEL: KARGER. ISSN 2296-5262
Janning, M., Sueptitz, J., Albers-Leischner, C., Delpy, P., Tufman, A., Velthaus-Rusik, J-L, Reck, M., Jung, A., Kauffmann-Guerrero, D., Bonzheim, I, Braendlein, S., Hummel, H-D, Wiesweg, M., Schildhaus, H-U, Stratmann, J. A., Sebastian, M., Alt, J., Buth, J., Esposito, I, Berger, J., Toegel, L., Saalfeld, F. C., Wermke, M., Merkelbach-Bruse, S., Hillmer, A. M., Klauschen, F., Bokemeyer, C., Buettner, R., Wolf, J. and Loges, S. (2022). Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNuM). Ann. Oncol., 33 (6). S. 602 - 616. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Michels, S., Westphal, T., Nogova, L., Scheffler, M., Deschler-Baier, B., Sebastian, M., Schuler, M., Wermke, M., Abdulla, D. S. Y., Fischer, R. N., Koleczko, S., Kron, A., Pinto, A., Riedel, R., Weber, J. -P., Fassunke, J., Merkelbach-Bruse, S., Haverkamp, H., Hellmich, M., Buettner, R. and Wolf, J. (2020). EATON: A phase I dose-escalation trial of nazartinib (EGF816) and trametinib in EGFR-mutant non-small cell lung cancer (NSCLC) - preliminary data. Oncol. Res. Treat., 43 (SUPPL 4). S. 148 - 149. BASEL: KARGER. ISSN 2296-5262
Nogova, L., Malchers, F., Hillmer, A. M., Merkelbach-Bruse, S., Pinto, A., Scheel, A. H., Siemanowski, J., Ueckeroth, F., Scheffler, M., Hummel, H. -D., Kern, J., Wermke, M., Kolbe, M., Grohe, C., Stratmann, J., Sebastian, M., Trummer, A., Weber, J. -P., Westphal, T., Michels, S., Koleczko, S., Sueptitz, J., Keser, E., Kron, A., Riedel, R., Abdulla, D. S. Y., Zadoyan, G., Sweiti, H., Santiago-Walker, A., Rothe, A., Draube, A., Sandler, A., Rodermann, E., Linck, D., Thomas, R. K., Buettner, R. and Wolf, J. (2020). FIND: a phase II study to evaluate the efficacy of erdafitinib in FGFR-altered NSCLC. Oncol. Res. Treat., 43 (SUPPL 4). S. 146 - 148. BASEL: KARGER. ISSN 2296-5262
Schuler, M., Cassier, P., Penel, N., Cathomas, R., Richly, H., Schostak, M., Janitzky, A., Wermke, M., Nogova, L., Tai, D., Sayehli, C., Gruellich, C., Grande, E., Navarro, A., Park, S. H., Nogai, H., Bender, S., Ellinghaus, P. and Joerger, M. (2018). Rogaratinib in patients with advanced urothelial carcinomas selected for tumor FGFR mRNA expression and impact of mutations in the FGFR signaling pathway. Oncol. Res. Treat., 41. S. 321 - 322. BASEL: KARGER. ISSN 2296-5262